Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$5.82B |
| 2 |
Eli Lilly
LLY
|
+$3.89B |
| 3 |
Starbucks
SBUX
|
+$3.58B |
| 4 |
Dominion Energy
D
|
+$1.19B |
| 5 |
Arista Networks
ANET
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$5.76B |
| 2 |
Salesforce
CRM
|
+$2.51B |
| 3 |
Gilead Sciences
GILD
|
+$2.5B |
| 4 |
GE HealthCare
GEHC
|
+$2.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.65B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.78% |
| 2 | Consumer Discretionary | 13.64% |
| 3 | Healthcare | 12.72% |
| 4 | Industrials | 11.43% |
| 5 | Financials | 9.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Haemonetics
HAE
$4.14B
| $85M | 0.02% |
1,139,043
-438,280
| -28% | -$29M |
|
302
Patrick Industries
PATK
$2.78B
| $84.4M | 0.02% |
914,516
-700,950
| -43% | -$59.6M |
|
303
Alaska Air
ALK
$5.34B
| $84.1M | 0.02% |
1,700,000
| – | – |
|
304
First Advantage
FA
$3.74B
| $83.8M | 0.02% |
5,044,562
-986,238
| -16% | -$15.9M |
|
305
Matsons
MATX
$6.44B
| $82.3M | 0.02% |
738,891
+11,683
| +2% | +$1.28M |
|
306
SS&C Technologies
SSNC
$18.9B
| $79.8M | 0.02% |
963,763
-99,987
| -9% | -$7.86M |
|
307
nCino
NCNO
$2.11B
| $79.1M | 0.02% |
2,826,919
| – | – |
|
308
Encompass Health
EHC
$12.2B
| $79M | 0.02% |
644,233
| – | – |
|
309
Boot Barn
BOOT
$5B
| $78.7M | 0.02% |
518,007
+55,389
| +12% | +$7.35M |
|
310
Vale
VALE
$58.9B
| $78.6M | 0.02% |
8,099,417
+17,199
| +0.2% | +$162K |
|
311
Applied Industrial Technologies
AIT
$13.1B
| $78M | 0.02% |
335,622
+1,523
| +0.5% | +$346K |
|
312
Lamb Weston
LW
$7.41B
| $76.2M | 0.02% |
1,470,000
+124,749
| +9% | +$6.68M |
|
313
Southern Company
SO
$107B
| $75.7M | 0.02% |
824,394
+281
| +0% | +$25.2K |
|
314
Essent Group
ESNT
$6.15B
| $74.3M | 0.01% |
1,224,193
+5,821
| +0.5% | +$335K |
|
315
Lowe's Companies
LOW
$122B
| $73.1M | 0.01% |
329,672
+39,752
| +14% | +$8.87M |
|
316
State Street
STT
$52.1B
| $72.5M | 0.01% |
681,940
-78,060
| -10% | -$7.22M |
|
317
Deere & Co
DE
$165B
| $71.4M | 0.01% |
140,335
+957
| +0.7% | +$469K |
|
318
Elastic
ESTC
$8.39B
| $69.9M | 0.01% |
828,543
+4,318
| +0.5% | +$365K |
|
319
First American
FAF
$7.43B
| $68.9M | 0.01% |
+1,122,623
| New | +$66.6M |
|
320
GSK
GSK
$101B
| $68.2M | 0.01% |
1,776,812
+14,654
| +0.8% | +$560K |
|
321
Denali Therapeutics
DNLI
$4.06B
| $66.5M | 0.01% |
4,750,579
-14,558
| -0.3% | -$205K |
|
322
Nutrien
NTR
$32B
| $66M | 0.01% |
1,133,777
+7,549
| +0.7% | +$427K |
|
323
Western Union
WU
$2.28B
| $64.7M | 0.01% |
7,679,907
+9,331
| +0.1% | +$88.7K |
|
324
Tetra Tech
TTEK
$9.13B
| $64.3M | 0.01% |
+1,787,103
| New | +$59.5M |
|
|
FISV
325
Fiserv Inc
FISV
$28.2B
| $63.6M | 0.01% |
369,148
+2,518
| +0.7% | +$457K |
|
Similar funds
Capital Research Global Investors's Q2 2025 Portfolio in Review
As of Q2 2025, Capital Research Global Investors held 486 positions worth $499B, up 8.6% from $460B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Capital Research Global Investors withdrew a net $17.7B in Q2 2025, closing 55 positions and reducing 156 holdings. Its most notable exit was Charter Communications, an estimated $600M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Capital Research Global Investors opened a new position in Microchip Technology worth $1.1B.
- Capital Research Global Investors's largest Q2 2025 buy was Microchip Technology: 15,650,335 shares worth $1.1B.
- Capital Research Global Investors added most to NVIDIA in Q2 2025, an estimated $5.82B increase.
- Capital Research Global Investors's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $5.76B.
- Capital Research Global Investors fully exited Charter Communications in Q2 2025, selling an estimated $600M.
- Capital Research Global Investors's ten largest holdings make up 36% of its $499B portfolio in Q2 2025.
- Capital Research Global Investors opened 28 new positions and closed 55 in Q2 2025.
- Capital Research Global Investors's portfolio value rose 8.6% quarter-over-quarter to $499B.
Based on Capital Research Global Investors's 13F filing for Q2 2025, filed 13 Aug 2025.